Prelude Capital Management’s Dicerna Pharmaceuticals, Inc. DRNA Stock Holding History

Prelude Capital Management’s Portfolio DRNA Stock Details DRNA Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2021 Q2	–	Sell	-33,943	Closed	-$868K	–	2130
2021 Q1	$868K	Buy	+33,943	New	+$867K	0.02%	652
2020 Q4	–	Sell	-200	Closed	-$4K	–	2211
2020 Q3	$4K	Sell	200 -3,300	-94%	-$68.3K	﹤0.01%	1607
2020 Q2	$89K	Buy	+3,500	New	+$75.4K	﹤0.01%	987
2017 Q2	–	Sell	-1,200	Closed	-$4K	–	1957
2017 Q1	$4K	Buy	1,200 +900	+300%	+$2.53K	﹤0.01%	1428
2016 Q4	$1K	Buy	+300	New	+$1.07K	﹤0.01%	1505

Other funds holding DRNA

RTW Investments New York $10B AUM 135.35% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return

BCLSI

Bain Capital Life Sciences Investors Boston, Massachusetts $1.11B AUM 171.34% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return

ACM

Aquilo Capital Management San Francisco, California $55.8M AUM 41.76% 1-Year Est. Return

Loomis, Sayles & Company Boston, Massachusetts $74.3B AUM 24.01% 1-Year Est. Return

JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return

Prelude Capital Management's DRNA Position: Q2 2021 in Review

Prelude Capital Management sold out of Dicerna Pharmaceuticals, Inc. (DRNA) in Q2 2021, closing a stake of 33,943 shares — an estimated $868K sold.

Prelude Capital Management first reported a position in DRNA in Q4 2016 and held it in 5 quarters. The position peaked at $868K in Q1 2021. 203 funds tracked by Wall St. Rank hold DRNA as of Q2 2021.

Prelude Capital Management reported no remaining Dicerna Pharmaceuticals, Inc. position as of Q2 2021 after selling out during the quarter.
Prelude Capital Management sold 33,943 Dicerna Pharmaceuticals, Inc. shares in Q2 2021, an estimated $868K.
Prelude Capital Management first reported a position in Dicerna Pharmaceuticals, Inc. in Q4 2016 and held it in 5 quarters.
Prelude Capital Management's Dicerna Pharmaceuticals, Inc. position peaked at $868K in Q1 2021.
203 funds tracked by Wall St. Rank held Dicerna Pharmaceuticals, Inc. as of Q2 2021.

Based on Prelude Capital Management's 13F filing for Q2 2021, filed 16 Aug 2021.